Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apitope Upbeat After Merck Returns Multiple Sclerosis Candidate

Executive Summary

With cladribine battling it out again with regulatory authorities for approval in multiple sclerosis, Merck decides to hand back rights to Apitope's Phase II MS drug candidate.


Related Content

ECTRIMS 2016: What Future For Merck KGaA’s Cladribine?
Hemophilia A And Graves' Focus For Freshly Financed Apitope


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts